Vertex Pharmaceutic (VRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 06-2026 | 03-2026 | 12-2025 | 09-2025 | 06-2025 | |
| Sales | 3,333,900 | 2,986,900 | 3,190,000 | 3,076,400 | 2,964,700 |
| Cost of Goods | 489,200 | 392,800 | 466,000 | 414,800 | 407,500 |
| Gross Profit | 2,844,700 | 2,594,100 | 2,724,000 | 2,661,600 | 2,557,200 |
| Operating Expenses | 1,598,000 | 1,456,800 | 1,518,100 | 1,476,200 | 1,406,600 |
| Operating Income | 1,246,900 | 1,138,100 | 1,205,900 | 1,186,200 | 1,151,100 |
| Interest Expense | 0 | 0 | 10,000 | 3,300 | 0 |
| Other Income | 144,900 | 114,800 | 135,100 | 115,900 | 131,900 |
| Pre-tax Income | 1,391,800 | 1,252,900 | 1,331,000 | 1,298,800 | 1,283,000 |
| Income Tax | 292,000 | 221,500 | 139,900 | 215,900 | 250,100 |
| Net Income Continuous | 1,099,800 | 1,031,400 | 1,191,100 | 1,082,900 | 1,032,900 |
| Net Income | $1,099,800 | $1,031,400 | $1,191,100 | $1,082,900 | $1,032,900 |
| EPS Basic Total Ops | 4.34 | 4.06 | 4.68 | 4.24 | 4.02 |
| EPS Basic Continuous Ops | 4.34 | 4.06 | 4.68 | 4.24 | 4.02 |
| EPS Diluted Total Ops | 4.31 | 4.02 | 4.64 | 4.20 | 3.99 |
| EPS Diluted Continuous Ops | 4.31 | 4.02 | 4.64 | 4.20 | 3.99 |
| EPS Diluted Before Non-Recurring Items | N/A | 3.95 | 4.65 | 4.22 | 4.00 |
| EBITDA(a) | $1,303,400 | $1,194,000 | $1,261,601 | $1,240,200 | $1,202,800 |